CD22 and acute lymphoblastic leukemia: In a phase I trial in predominantly B-ALL, anti-CD22 CAR-T cells achieved a CR rate of 70% in 58 patients with a median relapse-free survival of 6 months and an overall survival of 13.4 months.17 Minimal residual disease (MRD)–negative CR correlated with higher CD22 site density.